

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_76903
Title of the Manuscript:	IL-33 AND IL-1 α MAY BE ASSOCIATED WITH OVARIAN CANCER METASTASIS
Type of the Article	

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://peerreviewcentral.com/page/manuscript-withdrawal-policy>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments	<p>1.The author used a case control study approach to compare the results; nothing is mentioned in the study regarding the clinical history of the patients who had ovarian cancer if they had been evaluated for ovarian cancer metastasis or any medical illness which might be affecting the results, or if they had any imaging investigations to confirm if they had metastasis. Furthermore, they didn't mention if those patients underwent any surgeries or received any adjuvant chemotherapy which might be affecting the results. Lastly the age of the median age of the sample group is not mentioned.</p> <p>2. The author didn't classify the findings to the subgroups of ovarian cancer patients and the correlation between the findings and the clinical presentation if it's an inflammatory process or primarily from the cancer itself.</p> <p>3. The author mentioned in the conclusion that targeting these inflammatory cytokines may act as a novel strategy however the author didn't mention how this would be applicable from a clinical perspective.</p> <p>4. I quote {, IL-10 has positive correlation with advanced stage and poor prognosis of disease} how the author did classify the stages of the disease, did the author rely on FIGO classification?</p> <p>5. The author wrote {This research was performed by ethical committee of Institute of Molecular Biology and Biotechnology (IMBB), The University of Lahore}, can the author clarify what does it mean? is it the ethics including the consent?</p> <p>6. The title of the study is not related to the context of the study, discussion and conclusion.</p>	
<u>Minor</u> REVISION comments	Bar graphs should be included in the body of the study	
<u>Optional/General</u> comments	English and grammatical correction.	

Review Form 1.6

PART 2:

	Reviewer’s comment	Author’s comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	

Reviewer Details:

Name:	Kareem Haloub
Department, University & Country	The University of Melbourne, Australia